Zacks Investment Research Downgrades Ohr Pharmaceutical Inc. (OHRP) to Hold
According to Zacks, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York. “
Several other research firms also recently weighed in on OHRP. Brean Capital assumed coverage on Ohr Pharmaceutical in a research report on Tuesday, October 4th. They set a hold rating for the company. Roth Capital reiterated a buy rating and set a $13.00 target price on shares of Ohr Pharmaceutical in a research report on Thursday, June 16th.
Ohr Pharmaceutical (NASDAQ:OHRP) last released its earnings results on Tuesday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03.
Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors increased its stake in Ohr Pharmaceutical by 14.8% in the second quarter. BlackRock Fund Advisors now owns 75,333 shares of the company’s stock valued at $206,000 after buying an additional 9,685 shares during the last quarter. Vanguard Group Inc. increased its stake in Ohr Pharmaceutical by 1.1% in the second quarter. Vanguard Group Inc. now owns 922,616 shares of the company’s stock valued at $2,528,000 after buying an additional 9,763 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Ohr Pharmaceutical during the second quarter valued at $144,000. Bank of New York Mellon Corp increased its stake in Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock valued at $164,000 after buying an additional 757 shares during the last quarter. Finally, Opaleye Management Inc. purchased a new stake in Ohr Pharmaceutical during the first quarter valued at $1,175,000. Hedge funds and other institutional investors own 11.32% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.